Search Result

Results for "

cotransporter 2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Isotope-Labeled Compounds (1) Reactive Oxygen Species (1) SGLT (21)
By Research Areas:	Cancer (4) Endocrinology (1) Metabolic Disease (20)

Inhibitors & Agonists

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: Na+/HCO3- Cotransporter NKCC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15409

Empagliflozin Maximum Cited Publications 60 Publications Verification BI 10773	SGLT	Metabolic Disease
Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC₅₀ of 3.1 nM for human SGLT-2 .

HY-109144

Enavogliflozin DWP-16001	SGLT	Metabolic Disease
Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor .

HY-15409S

Empagliflozin-d4 BI 10773-d₄	SGLT	Metabolic Disease
Empagliflozin-d₄ is deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2[1].

HY-109018

Velagliflozin 1 Publications Verification	SGLT	Metabolic Disease
Velagliflozin is an orally available sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity.

HY-116223

Tianagliflozin	SGLT	Metabolic Disease
Tianagliflozin is a sodium/glucose cotransporter 2 (SGLT-2) inhibitor with potential for investigation in type 2 diabetes .

HY-109018A

Velagliflozin proline 1 Publications Verification	SGLT	Metabolic Disease
Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .

HY-15409R

Empagliflozin (Standard)	SGLT	Metabolic Disease
Empagliflozin (Standard) is the analytical standard of Empagliflozin. This product is intended for research and analytical applications. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC₅₀ of 3.1 nM for human SGLT-2 .

HY-153113

Rongliflozin DJT1116PG	SGLT	Endocrinology
Rongliflozin (DJT1116PG) is a selective and orally active inhibitor of sodium-glucose co-transporter-2 (SGLT-2). Rongliflozin can be used for the research of type 2 diabetes mellitus (T2DM) .

HY-13414

Remogliflozin Remogliflozin A	SGLT	Metabolic Disease
Remogliflozin is a potent and selective inhibitor of SGLT2 (sodium-glucose cotransporter 2) with K_is of 12.4 and 26 nM for human and rat SGLT2, respectively. Remogliflozin is the active form of Remogliflozin etabonate(HY-14945) .

HY-14902

Tofogliflozin CSG452	SGLT	Metabolic Disease
Tofogliflozin(CSG-452) is a potent and highly specific sodium/glucose cotransporter 2(SGLT2) inhibitor with Ki values of 2.9, 14.9, and 6.4 nM for human, rat, and mouse SGLT2.

HY-15461

Ertugliflozin 2 Publications Verification PF-04971729	SGLT	Metabolic Disease
Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC₅₀ of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus .

HY-109018B

Velagliflozin proline hydrate 1 Publications Verification	SGLT	Metabolic Disease
Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .

HY-10450

Dapagliflozin 35+ Cited Publications BMS-512148	SGLT	Metabolic Disease Cancer
Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury .

HY-15461A

Ertugliflozin L-pyroglutamic acid 2 Publications Verification PF-04971729 L-pyroglutamic acid	SGLT	Metabolic Disease
Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC₅₀ of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus .

HY-15461R

Ertugliflozin (Standard)	SGLT	Metabolic Disease
Ertugliflozin (Standard) is the analytical standard of Ertugliflozin. This product is intended for research and analytical applications. Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC₅₀ of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus .

HY-15461S

Ertugliflozin-d5 PF-04971729-d₅	SGLT	Metabolic Disease
Ertugliflozin-d₅ is the deuterium labeled Ertugliflozin[1]. Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2[2]. Has the potential for the treatment of type 2 diabetes mellitus[3].

HY-15461S1

Ertugliflozin-d9 PF-04971729-d₉	SGLT Isotope-Labeled Compounds	Metabolic Disease
Ertugliflozin-d₉ is deuterated labeled Ertugliflozin (HY-15461). Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC₅₀ of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus .

HY-13413

Tofogliflozin (hydrate) 4 Publications Verification CSG-452 hydrate	SGLT Reactive Oxygen Species	Metabolic Disease
Tofogliflozin hydrate (CSG-452 hydrate) is a potent and highly specific *sodium/glucose cotransporter 2* (SGLT2) inhibitor with an IC₅₀ of 2.9 nM and K_i values of 2.9 nM, 14.9 nM, and 6.4 nM for human, rat, and mouse SGLT2 . Tofogliflozin partially inhibits high glucose-induced reactive oxyen species (ROS)** generation in tubular cells .

HY-10450R

Dapagliflozin (Standard)	SGLT	Metabolic Disease Cancer
Dapagliflozin (Standard) is the analytical standard of Dapagliflozin. This product is intended for research and analytical applications. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury .

HY-10450A

Dapagliflozin ((2S)-1,2-propanediol, hydrate) 35+ Cited Publications BMS-512148 (2S)-1,2-propanediol, hydrate	SGLT	Metabolic Disease Cancer
Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin ((2S)-1,2-propanediol, hydrate), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin ((2S)-1,2-propanediol, hydrate) induces HIF1 expression and attenuates renal IR injury .

HY-10450AR

Dapagliflozin ((2S)-1,2-propanediol, hydrate) (Standard)	SGLT	Metabolic Disease Cancer
Dapagliflozin ((2S)-1,2-propanediol, hydrate) (Standard) is the analytical standard of Dapagliflozin ((2S)-1,2-propanediol, hydrate). This product is intended for research and analytical applications. Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin ((2S)-1,2-propanediol, hydrate), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin ((2S)-1,2-propanediol, hydrate) induces HIF1 expression and attenuates renal IR injury .

Species:	Human (2)
Tag:	GFP (1) His (2) Strep (2) Flag (1)
Source:	HEK293 (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P702022

	SLC12A2 Protein, Human (Sf9, His, Strep, FLAG) SLC12A2; Solute carrier family 12 member 2; Basolateral Na-K-Cl symporter; Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2	Human	HEK293
	SLC12A2 Protein mediates electroneutral transport of chloride, potassium, and/or sodium ions across the membrane, crucial for regulating ionic balance and cell volume. SLC12A2 Protein, Human (HEK293, His, Strep, FLAG) is the recombinant human-derived SLC12A2 protein, expressed by HEK293 insect cells , with N-Strep, C-Flag, N-8*His labeled tag. The total length of SLC12A2 Protein, Human (HEK293, His, Strep, FLAG) is 1211 a.a., .

HY-P703077

	SLC12A2 Protein, Human (HEK293, His, Strep, GFP) SLC12A2; Solute carrier family 12 member 2; Basolateral Na-K-Cl symporter; Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2	Human	HEK293
	SLC12A2 Protein mediates electroneutral transport of chloride, potassium, and/or sodium ions across the membrane, crucial for regulating ionic balance and cell volume. SLC12A2 Protein, Human (HEK293, His, Strep, GFP) is the recombinant human-derived SLC12A2 protein, expressed by HEK293 , with N-Strep, N-EGF, N-His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-15409S

Empagliflozin-d4
Empagliflozin-d₄ is deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2[1].

HY-15461S

Ertugliflozin-d5
Ertugliflozin-d₅ is the deuterium labeled Ertugliflozin[1]. Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2[2]. Has the potential for the treatment of type 2 diabetes mellitus[3].

HY-15461S1

Ertugliflozin-d9
Ertugliflozin-d₉ is deuterated labeled Ertugliflozin (HY-15461). Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC₅₀ of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81437

	SLC34A2 Antibody (YA1182) SLC34A2; Sodium-dependent phosphate transport protein 2B; Sodium-phosphate transport protein 2B; Na(+)-dependent phosphate cotransporter 2B; NaPi3b; Sodium/phosphate cotransporter 2B (Na(+)/Pi cotransporter 2B; NaPi-2b); Solute carrier family 34 member 2	IHC-P	Human
	SLC34A2 Antibody (YA1182) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1182), targeting SLC34A2. SLC34A2 Antibody (YA1182) can be used for IHC-P experiment in human background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.